Furthermore, we have shown that VEGF165b inhibition in ischemic muscle produces therapeutic perfusion recovery in multiple preclinical PAD models9,10,12, including endothelial nitric oxide synthase (eNOS)-KO, Myoglobin Transgenic, and Type-2 Diabetic PAD mice12. This evidence concerns the gene NOS3 and peripheral arterial disease.